Canada markets open in 52 minutes
  • S&P/TSX

    20,188.43
    +90.93 (+0.45%)
     
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • DOW

    35,061.55
    +238.15 (+0.68%)
     
  • CAD/USD

    0.7955
    -0.0006 (-0.07%)
     
  • CRUDE OIL

    72.10
    +0.03 (+0.04%)
     
  • BTC-CAD

    48,848.97
    +5,394.60 (+12.41%)
     
  • CMC Crypto 200

    929.13
    +135.40 (+17.06%)
     
  • GOLD FUTURES

    1,804.20
    +2.40 (+0.13%)
     
  • RUSSELL 2000

    2,209.65
    +10.17 (+0.46%)
     
  • 10-Yr Bond

    1.2510
    -0.0350 (-2.72%)
     
  • NASDAQ futures

    15,072.00
    -26.00 (-0.17%)
     
  • VOLATILITY

    18.36
    +0.67 (+3.79%)
     
  • FTSE

    7,025.07
    -2.51 (-0.04%)
     
  • NIKKEI 225

    27,833.29
    +285.29 (+1.04%)
     
  • CAD/EUR

    0.6748
    -0.0011 (-0.16%)
     

Investors Who Bought Insmed (NASDAQ:INSM) Shares Five Years Ago Are Now Up 204%

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

It hasn't been the best quarter for Insmed Incorporated (NASDAQ:INSM) shareholders, since the share price has fallen 10% in that time. But in stark contrast, the returns over the last half decade have impressed. Indeed, the share price is up an impressive 204% in that time. We think it's more important to dwell on the long term returns than the short term returns. Only time will tell if there is still too much optimism currently reflected in the share price.

See our latest analysis for Insmed

Given that Insmed didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

Take a more thorough look at Insmed's financial health with this free report on its balance sheet.

A Different Perspective

Insmed shareholders gained a total return of 50% during the year. Unfortunately this falls short of the market return. The silver lining is that the gain was actually better than the average annual return of 25% per year over five year. This suggests the company might be improving over time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Insmed is showing 3 warning signs in our investment analysis , you should know about...

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting